It also records Beyfortus product sales from products supplied to partner ... Year to date, the stock has declined 3.8% ...

Here’s how it works. Space can be a wondrous place, and we've got the pictures to prove it! Take a look at our favorite space pictures here, and if you're wondering what happened to today in ...

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...

Key Takeaways Zacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture ...

Not content with taking on the respiratory syncytial virus (RSV) prevention market with its antibody-based therapy Beyfortus, AstraZeneca has agreed to buy US biotech Icosavax and its phase 3 ...

ICC chief prosecutor says will 'continue functions' ...

As one of the leading causes of hospitalization in infants, RSV can be mitigated through the administration of nirsevimab (brand name Beyfortus), an RSV preventive antibody. Unlike vaccines that ...

ESPOO, Finland, Nov. 7, 2024 /PRNewswire/ -- Serres has been granted a substantial research grant of 1.8 million from Business Finland. Serres is a forerunner in designing and manufacturing surgical ...

PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and Prevention GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) ...

Eliminating fake vaccine news with pharmacist, nurse, and physician review.